ANG1005: Updated Phase I/II data

Updated data from an open-label, dose-escalation Phase I/II trial in 56 patients showed that 71% of patients receiving >=420 mg/m 2 IV ANG1005 achieved stable disease (SD) or better, including 10 pati...